货号:A570568 同义名: NVP-QAW039;QAW039
Fevipiprant is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Fevipiprant is a potent and selective CRTh2 (DP2) receptor antagonist with Ki value of 4nM in a human DP2 receptor scintillation proximity binding assay, and IC50 values of 0.4nM for in both isolated human eosinophil shape change assay and human whole blood eosinophil shape change assay. Fevipiprant dose-dependently antagonize PGD2-stimulated [35S]-GTPγS activation at human CRTh2 receptors expressed in membranes from CHO cells. It inhibited DK-PGD2 induced cytokine production, including IL-4, IL-5 and IL-13, with IC50 values of 3.1nM, 2.6nM and 1.4nM in human CD4+ Th2 cells. |
作用机制 | Fevipiprant could bind to CRTh2 receptor through competition with the native agonist PGD2.[2] |
Dose | Rat: 0.03 mg/kg - 0.1 mg/kg[1] (p.o.) | ||||||||||||||
Administration | p.o. | ||||||||||||||
Pharmacokinetics |
|
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.35mL 0.47mL 0.23mL |
11.73mL 2.35mL 1.17mL |
23.45mL 4.69mL 2.35mL |
CAS号 | 872365-14-5 |
分子式 | C19H17F3N2O4S |
分子量 | 426.409 |
别名 | NVP-QAW039;QAW039;NVP-QAW-039 QAW-039 |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry,2-8°C |
溶解方案 |
DMSO: 30 mg/mL(70.35 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
动物实验配方 |